Discovery of a Biased Kelch-like ECH-Associated Protein 1-p62 (Keap1-p62) Protein-Protein Interaction (PPI) Inhibitor for the Management of p62 Aberrant Hepatocellular Carcinoma

  • J Med Chem. 2026 Jun 11;69(11):13141-13164. doi: 10.1021/acs.jmedchem.6c00096.
Ziquan Zhao  1 ,  Hongjin Lu  1 ,  Jinshen Zhang  1 ,  Jinglong Zhao  1 ,  Junjie Wang  1 ,  Tianbao Zhu  1 ,  Shicheng Xu  1 ,  Qidong You  1 ,  Mengchen Lu  2 ,  Zhengyu Jiang  1
Affiliations
  • 1. Jiang Su Key Laboratory of Drug Design and Optimization and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
  • 2. Department of Medicinal Chemistry, College of Pharmaceutical Sciences, Soochow University Medical College, Suzhou 215123, China.
PMID: 42216892 DOI: 10.1021/acs.jmedchem.6c00096
Abstract

Nuclear factor erythroid 2-related factor 2 (Nrf2) is a pleiotropic transcription factor essential for cellular defense. Extensive research has demonstrated its oncogenic role, positioning Nrf2 as a promising target for Cancer therapy. However, achieving tumor-specific Nrf2 inhibition remains a challenge. Herein, we report the discovery of 13, a biased inhibitor of Kelch-like ECH-associated protein 1-phosphorylated p62 (Keap1-p-p62) interaction, as a selective and effective Nrf2 inhibitor. In fluorescence polarization assays, 13 showed potent Keap1-p-p62 inhibitory activity (IC50 = 0.11 μM) and high selectivity over the inhibition of Keap1-Nrf2 interaction. Notably, 13 specifically inhibited Nrf2 activity in p62 aberrant hepatocellular carcinoma (HCC) cells by selectively disrupting Keap1-p-p62 interaction and normalizing Nrf2 ubiquitination. Furthermore, cotreatment with 13 sensitized p62 aberrant HCC to Ferroptosis induced by sorafenib (TGI = 95.3%). Overall, our study identifies a biased Keap1-p-p62 inhibitor 13 as a targeted Nrf2 inhibition therapy and provides valuable insights into HCC treatment.

Products